LesothoTuberculosis profile
Population  2017 2.2 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1 (0.55–1.7) 46 (25–75)
Mortality (HIV+TB only) 4.6 (2.9–6.7) 206 (128–302)
Incidence  (includes HIV+TB) 15 (9.6–21) 665 (430–949)
Incidence (HIV+TB only) 11 (6.7–15) 470 (298–680)
Incidence (MDR/RR-TB)** 1.1 (0.61–1.7) 50 (27–78)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 1 (0.93–1.1) 4.6 (3.6–5.7) 5.7 (4.3–7.1)
Males 1.1 (1–1.3) 8 (5.7–10) 9.2 (6.4–12)
Total 2.2 (1.8–2.5) 13 (8.1–17) 15 (9.6–21)
TB case notifications, 2017  
Total cases notified 7 271
Total new and relapse 7 117
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 92%
          - % pulmonary 89%
          - % bacteriologically confirmed among pulmonary 58%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 48% (34–74)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.39 (0.2–0.6)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 4 690 70%
          - on antiretroviral therapy 4 310 92%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  410
(330–490)
Estimated % of TB cases with MDR/RR-TB 4.8% (3.7–6) 14% (9.5–18)  
% notified tested for rifampicin resistance 63%   3 839
MDR/RR-TB cases tested for resistance to second-line drugs    
Laboratory-confirmed cases MDR/RR-TB: 351, XDR-TB:
Patients started on treatment **** MDR/RR-TB: 151, XDR-TB:
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 77% 7 291
Previously treated cases, excluding relapse, registered in 2016 68% 228
HIV-positive TB cases registered in 2016 74% 5 085
MDR/RR-TB cases started on second-line treatment in 2015 66% 210
XDR-TB cases started on second-line treatment in 2015    
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2018  
National TB budget (US$ millions) 3.3
Funding source: 30% domestic, 55% international, 15% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-09-26 Data: www.who.int/tb/data